# DIPPER (NCT03427827)

> PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma

No report yet. It can be ordered.

- Drugs tested: camrelizumab
- Indication: locoregionally advanced nasopharyngeal carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03427827
- Phase: PHASE3
- Status: UNKNOWN
- Sponsor: Sun Yat-sen University
- Conditions: Nasopharyngeal Neoplasms
- Interventions: Camrelizumab
- Enrollment: 450
- Primary outcome: failure-free survival

## Indexed commentary on DIPPER so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 9 posts on X
- 1 YouTube video
- 1 podcast episode

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=dipper-nct03427827

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03427827", "email": "<work email>"}; the inbox owner confirms by the emailed link.